CENTURY THERAPEUTICS INC (IPSC)
US15673T1007 - Common Stock
CENTURY THERAPEUTICS INC
NASDAQ:IPSC (4/26/2024, 4:01:52 PM)
2.88
-0.27 (-8.57%)
Company Profile
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 163 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-104 is a multi-specific collaboration program for acute myeloid leukemia.
Company Info
CENTURY THERAPEUTICS INC
25 N 38Th Street, 11Th Floor
PHILADELPHIA PENNSYLVANIA
P: 12159814000
CEO: Osvaldo Flores
Employees: 163
Website: https://www.centurytx.com/
IPSC News
4 days ago - Century Therapeutics, Inc.Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitPHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows:
16 days ago - Century Therapeutics, Inc.Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsCentury is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based...
18 days ago - Century Therapeutics, Inc.Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual MeetingPHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent...
IPSC Twits
Here you can normally see the latest stock twits on IPSC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
